C. Videbaek et al., In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by[I-123]IBZM and single photon emission computed tomography, J CEREBR B, 21(1), 2001, pp. 92-97
This study examines the feasibility of a steady-state bolus-integration met
hod with the dopamine D2/D3 receptor single photon emission computer tomogr
aphy (SPECT) tracer, [ I-123]IBZM, for determination of in vivo affinity of
haloperidol. The nonspecific binding of [I-123]IBZM was examined in the ra
t brain by infusion of haloperidol to plasma levels approximately 100 times
the Kd level in man. In humans, Kd for haloperidol binding was measured in
four healthy volunteers that were examined twice: once with partial dopami
ne D2/D3 receptor blockade obtained by a scheduled infusion of unlabeled ha
loperidol (0.7 mg total dosage), and once in an unblocked state. Blood samp
ling and SPECT were performed intermittently during 6 hours after intraveno
us [I-123]IBZM bolus injection. Plasma [I-123]IBZM was determined by octane
extraction. Plasma haloperidol was determined by a radioimmunoassay, and p
lasma protein binding was determined by equilibrium dialysis. In humans, th
e striatal D2/D3 receptor occupancy was 0.27 +/- 0.085 and the in vivo Kd f
or haloperidol was 0.25 +/- 0.1 nmol/L, which is comparable to Kd values as
obtained from in vitro studies. The authors conclude that steady-state [I-
123]IBZM SPECT studies allow for determination of dopamine D2/D3 receptor o
ccupancy in striatum and in vivo measurement of drug affinity to striatal d
opamine D2 and D3 receptors.